In present study, we found that the level of TLR3 expressing CD14+ monocytes was elevated in chronic hepatitis C patients and further increased at 12 weeks, but returned to baseline level at 24 weeks after treatment with IFNα-2b/RBV or PegIFNα-2a/RBV. Here, IFNA2 is linked to chronic hepatitis C virus infection.